Telix is a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals. Telix’s extensive pipeline for urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning is ...

Telix is focused on developing therapies for urologic (prostate and kidney), neurologic (brain) and musculoskeletal (sarcoma) cancers. The Precision Medicine unit support the Therapeutics unit by enabling the delivery of personalised theranostic solutions to market using Telix’s diagnostics.

2025年2月20日 · Telix today announces its financial results for the year ended 31 December 2024. All figures are in AU$ unless stated otherwise. Total revenue, driven primarily from sales of Illuccix® of $783.2 million, up by 56% 1 from $502.5 million in 2023, beating full year guidance 2.

Telix is a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals. Telix’s extensive pipeline for urologic oncology, neuro-oncology, musculoskeletal oncology and hematology is underpinned by a strong global supply, manufacturing and ...

Telix Pharmaceuticals的研发管线旨在解决前列腺癌、肾癌（肾癌）、脑癌（ 胶质母细胞瘤 ）和血液系统癌症（骨髓调节）以及一系列免疫和罕见疾病中未满足的重大医疗需求。 01 前列腺癌

2025年2月20日 · Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan.

2024年6月10日 · Telix Pharmaceuticals的技术使用靶向辐射成像和治疗相结合，有可能改变临床医生发现和治疗癌症和罕见疾病的方式，更好地为治疗决策提供信息，并为 ...

7月24日，专注于放射性核素偶联药物（RDC）领域的生物制药公司Telix Pharmaceuticals（“Telix”）发布公告，宣布已成功发行了价值6.5亿澳元（约合31亿人民币）的可转债。

2025年3月12日 · MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212 Pb) and successfully completed first production.The new generator technology, developed internally by Telix’s ...

2020年11月1日 · Telix是一家专注于RDC的生物技术公司，总部位于澳大利亚墨尔本，聚焦新型放射性核素-靶向分子药物偶联技术，并利用这一创新技术平台开展RDC在癌症治疗、诊断领域的开发及应用。